Adipotide (prohibitin-targeting peptide)

Classification

Targeted pro-apoptotic peptidomimetic (research only)

Approval status

Research only · Not approved for human use

Research status

Investigational / reference listing.

Molecular formula

Insufficient reliable evidence identified.

Molecular weight

Insufficient reliable evidence identified.

Sequence

Chimeric peptide designed to target white-fat vasculature in animal work.

Primary biological target

Insufficient reliable evidence identified.

Half-life

Insufficient reliable evidence identified.

Routes investigated

Insufficient reliable evidence identified.

Human evidence level

D — Primarily animal / preclinical evidence

Experimental fat-loss research agent with serious toxicity signals in animals. Not sold.

Proposed targeting of prohibitin in adipose vessels.

Renal toxicity reported in animal studies — not a cosmetic.

• Experimental adipose ablation in animals

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Overall human evidence grade: D · Primarily animal / preclinical evidence

Not an approved drug; safety concerns.

Animal, cell and in-vitro findings are listed separately from human effects.

Animal obesity models with toxicity.

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Kidney injury signals in animals.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for human use.

Not approved.

Educational warning.

1. [1] Encyclopaedia note

   Encyclopaedia note